Ignyta Announces RXDX-101 Phase I Data Abstract Accepted For Oral Presentation At The 2014 American Society of Clinical Oncology Annual Meeting
5/8/2014 7:41:59 AM
Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, today announced that an abstract regarding the presentation of interim results from the first-in-human ALKA-372-001 Phase I clinical trial of RXDX-101, the company’s proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, was selected for an oral presentation at the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
comments powered by